Ketoconazole Shampoo
Nizoral
Ketoconazole Shampoo (Nizoral) is a hormonal & sexual research compound. Antifungal that also has weak anti-androgenic activity at the follicle and reduces Malassezia, which drives scalp inflammation.
Ketoconazole Shampoo quick facts
| Reported research dose | 1–2%, 2–3x weekly, left on 3–5 minutes |
| Route | Topical |
| Frequency | 2–3x |
| Half-life | Local |
| Forms | Topical |
| Evidence level | Small trials show improved hair density versus non-medicated shampoo |
A cheap, low-risk third pillar next to finasteride and minoxidil. The contact time matters — rinsing straight away does very little. Won't do much on its own; worth its place as an adjunct.
How Ketoconazole Shampoo works
Antifungal that also has weak anti-androgenic activity at the follicle and reduces Malassezia, which drives scalp inflammation.
Proposed benefits
Scalp seborrheic dermatitis and dandruff, and an adjunct in pattern hair loss — an antifungal with weak topical anti-androgen activity.
Where to get Ketoconazole Shampoo
Buy Ketoconazole Shampoo at AlgoRx →The evidence for Ketoconazole Shampoo
Graded by what exists behind each claim.
✅ Clinically validated
- Randomized trial data supports 2% ketoconazole shampoo for seborrhoeic dermatitis and dandruff, where it is a first-line treatment. Smaller studies in androgenetic alopecia found improvements in hair density comparable to low-strength minoxidil.
📊 Correlative data
- Long-standing adjunct use in hair-loss routines, typically two or three times weekly. Reported experience is of a scalp-health effect that is easy to notice and a hair-density effect that is subtle.
🧪 Theoretical / extrapolated
- An antifungal that inhibits ergosterol synthesis, clearing *Malassezia* — which is what drives seborrhoeic dermatitis.
- The hair-loss rationale has two strands: reducing scalp inflammation that worsens follicular miniaturization, and weak local anti-androgen activity. The first is well supported; the second is the part doing most of the work in the marketing.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Ketoconazole Shampoo actually does
Ketoconazole has one licensed mechanism and one popular one, and only the first is settled. The licensed one is antifungal: it inhibits lanosterol 14α-demethylase, the fungal cytochrome P450 that makes ergosterol, so the yeast cannot build a membrane. On a scalp the target organism is Malassezia, whose lipase activity on sebum triglycerides generates free fatty acids that drive the inflammation of seborrhoeic dermatitis. Everything about dandruff, flaking and itch follows from that, and it is not in dispute.
The popular mechanism is that ketoconazole is an anti-androgen at the follicle, and the two papers that tested it disagree in a way that is more informative than either alone. Eil 1992 measured competitive displacement of the synthetic androgen [3H]R1881 from androgen receptors in dispersed, intact cultured human skin fibroblasts. There is a real interaction and Scatchard analysis called it competitive — but look at the concentration: 50% displacement required 6.4 ± 1.8 × 10−5 M ketoconazole. That is 64 micromolar, and the authors said so themselves: the dose required for 50% occupancy of the androgen receptor is not likely to be achieved in vivo, at least in plasma.
And in a different tissue the effect vanishes entirely. Ayub 1989 tested ketoconazole alongside bifonazole, clotrimazole, econazole, isoconazole, miconazole and tioconazole against [3H]R1881 binding to the prostatic androgen receptor and found the imidazoles without effect up to 100 µmol/L. They were only weak competitors of DHT binding to SHBG, inhibiting 20–53% at 100 µmol/L, with no effect on cortisol binding to CBG. That paper named the class’s actual endocrine mechanism, and it is not the receptor: inhibition of cytochrome P450-dependent steroidogenic enzymes.
So the honest reading of the receptor claim is this: whatever androgen-receptor interaction ketoconazole has is weak, tissue-dependent, absent in prostate at 100 µM, and needs 64 µM in skin fibroblasts. The real reason high-dose oral ketoconazole lowers testosterone is that it blocks the cytochromes that synthesize steroids Ayub 1989 — an enzyme effect in the adrenal and the gonad, which requires systemic exposure a rinse-off shampoo is specifically designed not to produce.
But here is the arithmetic that reframes the whole argument, and almost nobody does it. Ketoconazole’s molecular weight is about 531, so 64 µM is roughly 34 mg per liter — about 0.0034% w/v. A 2% shampoo is 20 grams per liter, which is about 590 times that concentration; a 1% shampoo is about 295 times it. Eil’s caveat was explicitly about plasma, and a shampoo is not trying to reach plasma. So the concentration in the bottle is not the limiting factor and never was. The entire question is what fraction of it penetrates to the androgen receptors in a follicle during three to five minutes of contact — and that number has never been measured by anybody.
Cell, rodent, human — and where it stops
Step one, cells, and the two results are already in tension. Human skin fibroblasts: competitive displacement at 64 µM, with the authors’ own caveat about plasma Eil 1992. Prostatic androgen receptor: no effect to 100 µM, with weak SHBG competition and a steroidogenic-enzyme mechanism instead Ayub 1989. Two receptor preparations, two answers, and no experiment has ever been done in a hair follicle — the only tissue that matters here.
Step two: there is no rodent step, and that is appropriate. The target organism lives on human scalp and the pharmacology is local. Nothing would be learned from a mouse that the human study below does not say better.
Step three, humans, and this is the entire clinical basis for the hair claim. Pierard-Franchimont 1998 compared 2% ketoconazole shampoo against unmedicated shampoo, with and without 2% minoxidil therapy, in androgenetic alopecia. The finding that gets quoted everywhere: hair density, hair size and the proportion of anagen follicles were improved almost similarly by both the ketoconazole and the minoxidil regimens. The finding that gets quoted nowhere: the sebum casual level appeared to be decreased by ketoconazole. That second result is the mechanistic clue, and it points at the antifungal and sebum arm rather than at the receptor.
Step four, and this is where the anti-androgen story actually comes from. Hugo Perez 2004 is a hypothesis paper. It proposes that 2% ketoconazole shampoo produces a local disruption of the DHT pathway and that using it as an adjunct to finasteride could lead to more complete DHT inhibition. It is a proposal, published as one, and it is the single most-cited source in this space for a mechanism that has never been demonstrated in a follicle.
Step five, the field’s own summary. Marks 2020 reviewed topical antiandrogens and concluded that topical formulations of finasteride, ketoconazole and C17P are promising, especially topical finasteride combined with topical minoxidil, and that more peer-reviewed studies are necessary before definitive recommendations can be made. “Promising” is a review’s word for a mechanism that has not been shown.
The obstacle, stated exactly, and it is a measurement obstacle rather than a biological one. The concentration in a 2% bottle is about 590-fold above the in-vitro androgen-receptor IC50 Eil 1992, so nothing about the arithmetic forbids a local effect. What is missing is the delivery number: no one has measured how much ketoconazole reaches a hair follicle after a normal application. And a second gap sits on top of it — the clinical study used 2% Pierard-Franchimont 1998, while the product most people buy over the counter is 1%, and no head-to-head comparison of 1% against 2% in androgenetic alopecia has ever been published.
Ketoconazole Shampoo pharmacokinetics — how much of it actually gets in
Route: topical, rinse-off, and that single design choice decides everything on this page. A shampoo sits on the scalp for three to five minutes, two or three times a week, and then most of it goes down the drain. Contact time is not a detail; it is the only exposure variable the user controls.
The oral comparator is the drug with the endocrine effects, and it is a different exposure entirely. Oral ketoconazole is well absorbed, is a potent inhibitor of hepatic cytochrome P450 3A4, and blocks the cytochrome P450-dependent steroidogenic enzymes Ayub 1989 — which is why the oral drug lowers testosterone, and why it carries hepatotoxicity and adrenal warnings. Those consequences require plasma concentrations. A rinse-off product is engineered to avoid producing them, and there is no injectable or systemic version of this product on this page.
What degrades it, in the two compartments that matter. Systemically, hepatic CYP3A4 handles ketoconazole and the drug inhibits that same enzyme, which is the basis of its very long oral interaction list. On the scalp there is essentially no metabolism to speak of — the fate of the applied dose is dilution, rinse-off, and binding. Ketoconazole is highly lipophilic, so it partitions into sebum and binds keratin, which is the plausible basis for a residual depot in the stratum corneum and the follicular infundibulum after rinsing. How large that depot is has never been measured.
The arithmetic, laid out, because it is the only quantitative handle anybody has. A 2% shampoo is 20 g/L and a 1% shampoo is 10 g/L. The in-vitro concentration for 50% androgen-receptor displacement is 6.4 × 10−5 M, or about 34 mg/L at a molecular weight of 531 Eil 1992. So the applied product carries roughly 590 times (2%) or 295 times (1%) the concentration needed — meaning a delivery efficiency of only 0.2% into the follicle would be enough to hit the in-vitro IC50 from a 2% product. That is not an implausible penetration fraction for a lipophilic molecule into a sebaceous follicle. It is also completely unmeasured, and stating both halves of that sentence is the only honest position available.
What would have to be true, and how you would know it was not
Four predictions. The first two are what should happen, the third cuts against the anti-androgen framing and is a genuine safety check, and the fourth is the experiment that costs nothing to run.
1. Scalp condition and sebum improve first, and reliably. This is the arm with the strongest evidence: Pierard-Franchimont 1998 found the sebum casual level decreased with ketoconazole. Flaking, itch and greasiness should change within two to four weeks. If they do not, the antifungal effect is not being achieved — which usually means contact time, not concentration — and nothing further is going to happen either.
2. Hair density needs a photograph, not a mirror. The endpoints in the one clinical study were hair density, hair size and the proportion of anagen follicles Pierard-Franchimont 1998, and the reported effect was comparable to 2% minoxidil — which is a real effect and a slow one. Take a standardized photograph at a fixed distance, a fixed part-line and fixed lighting at baseline and at 6 months. Anything shorter cannot resolve a change in a structure that grows about a centimetre a month.
3. The prediction that cuts against the anti-androgen framing, and it doubles as the safety check: serum androgens should be completely unchanged. Draw total testosterone, DHT and SHBG at baseline and at 12 weeks. The mechanism predicts flat lines: the receptor interaction requires 64 µM in a dish Eil 1992 and is absent in prostate at 100 µM Ayub 1989, and a rinse-off product should not produce systemic concentrations at all. So a fall in testosterone is not evidence the product is working — it is evidence that enough is being absorbed to inhibit steroidogenic cytochromes Ayub 1989, which is the oral drug’s mechanism and the oral drug’s problem. This is the one result on this page that should prompt stopping rather than continuing.
4. Contact time should matter more than concentration, and that is directly testable at home. The arithmetic says the bottle carries hundreds of times the concentration needed and the unknown is delivery Eil 1992. So the prediction is that a 5-minute contact at 1% beats an immediate rinse at 2%. Run 12 weeks with a timed 5-minute contact, then 12 weeks rinsing immediately, with the same photograph protocol and the same product. Nobody has published this comparison at any strength, and it is the single variable a user actually controls.
What nobody has tested yet
Nobody has measured how much ketoconazole reaches a hair follicle. This is the number the entire anti-androgen argument depends on, and its absence is why the argument has been repeated for twenty years without being settled. The experiment is routine dermatological pharmacology: apply the product normally, then sample the follicular contents by cyanoacrylate follicular biopsy or by a punch biopsy, and quantify by LC-MS/MS. Ten people, one visit each. Compare the answer with 34 mg/L Eil 1992 and the question is closed in either direction.
Nobody has compared 1% with 2% for hair. The clinical study used 2% Pierard-Franchimont 1998; the over-the-counter product in most markets is 1%. Those differ twofold in concentration and nothing is known about whether they differ at all in follicular delivery, because delivery has never been measured at either strength. A person buying the 1% bottle is using a product that has never been tested for the reason they bought it.
Nobody has separated the antifungal effect from the androgen effect, and one trial would do it. Run ketoconazole against an equally effective non-imidazole antifungal — zinc pyrithione, selenium sulfide or ciclopirox — with hair density as the endpoint and dandruff control matched. If both arms improve hair density equally, the benefit is anti-Malassezia and anti-inflammatory, and the receptor story is decoration. If ketoconazole wins, the receptor story survives. Twenty-five years after Pierard-Franchimont 1998, this has still not been run, and it is why Marks 2020 can only say “promising”.
And nobody has tested the finasteride combination that was proposed. Hugo Perez 2004 put forward ketoconazole as an adjunct to finasteride for more complete DHT inhibition — a specific, testable, two-arm proposal from 2004. No controlled trial of that combination has been published since. The hypothesis has been cited far more often than it has been examined.
Ketoconazole Shampoo — its own safety story, not its class's
The first thing to get right is which drug’s risks apply, because the wrong ones are quoted constantly. Oral ketoconazole is restricted in many markets over hepatotoxicity, adrenal suppression and QT prolongation. Those consequences come from systemic inhibition of hepatic CYP3A4 and of the cytochrome P450-dependent steroidogenic enzymes Ayub 1989, and they require plasma concentrations that a rinse-off topical is designed not to produce. Copying the oral label onto a shampoo page would be exactly the class-block error this site exists to fix.
What this product’s risks actually are: local, mild, and mostly about the vehicle. Scalp irritation, dryness, and changes in hair texture are the common complaints, and contact dermatitis when it occurs is frequently to a surfactant or fragrance in the formulation rather than to ketoconazole. That distinction is practical — it means switching brands at the same drug strength is a sensible response to irritation, where switching drugs would not be.
The specific behavior worth flagging is escalation, and the mechanism does not support it. The antifungal effect saturates: once Malassezia is suppressed, more contact time and more frequency do not suppress it further, and the sebum effect Pierard-Franchimont 1998 is not dose-linear either. Daily use of a detergent-based medicated shampoo mostly buys scalp dryness and barrier disruption, which can worsen the flaking it was applied for.
And the honest closing statement, which is not the one either side of this argument wants. The mechanism that is weak is the androgen-receptor one: 64 µM in skin fibroblasts Eil 1992, no effect at 100 µM in prostate Ayub 1989, and no follicular measurement in existence. The effect is a separate question, and there the one clinical study reported hair density and anagen proportion improving almost similarly to 2% minoxidil Pierard-Franchimont 1998. A weak mechanism is not a reason to stop using an antifungal shampoo that controls seborrhoeic dermatitis. It is a reason to stop describing it as an anti-androgen.
Sources read for this page
- Eil C. Ketoconazole binds to the human androgen receptor.. Horm Metab Res 1992 · PMID 1526623
- Ayub M. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem 1989 · PMID 2788775
- Pierard-Franchimont C. Ketoconazole shampoo: effect of long-term use in androgenic alopecia.. Dermatology 1998 · PMID 9669136
- Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men.. Med Hypotheses 2004 · PMID 14729013
- Marks DH. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris.. Am J Clin Dermatol 2020 · PMID 31832993
Ketoconazole Shampoo — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Applied to scalp, systemic exposure is low but not zero — and the predicted problems are the ones that occur when it is not zero.
- Minoxidil is a vasodilator, so the predicted systemic effects are dose-dependent: lowered blood pressure, tachycardia, fluid retention and ankle swelling. Oral minoxidil produces these reliably; topical produces them in people who use a lot, on damaged skin, or who absorb unusually well.
- Unwanted hair growth away from the scalp is the predictable consequence of a systemic hair-growth signal, and it is the most common reason people stop.
- The shed in the first weeks is expected — minoxidil pushes follicles into a new growth phase and the old hairs release first. Stopping because of it is the classic mistake.
What has actually been reported
- Contact dermatitis and scalp irritation are common, and are more often the propylene glycol vehicle than the drug — foam formulations exist for exactly that reason.
- Ketoconazole shampoo is well tolerated; the main issue is dryness.
How to reduce the risk
Same mechanism as the prediction.
- Apply to a dry scalp, not broken or freshly microneedled skin — absorption through compromised skin is the situation where a topical starts behaving systemically.
- Switch to foam if the vehicle is irritating rather than abandoning the drug.
- Any of this stops working when you stop using it. That is the mechanism, not a failure — the effect requires continued signal.
What it does to your bloodwork
A fact about the assay.
- Nothing routine for topical use. Blood pressure and resting heart rate if you are using a large volume or have moved to oral.
Don't run this if
- You have a cardiovascular condition and are considering ORAL minoxidil — that is a prescriber's decision, and it was a blood pressure drug before it was a hair drug.
- You have cats in the house. Minoxidil is severely toxic to them and residue transfer is a documented cause of death.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Ketoconazole Shampoo — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Ketoconazole Shampoo moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Ketoconazole Shampoo in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Ketoconazole Shampoo
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Total Testosterone | The baseline you can't reconstruct later |
| Free Testosterone | The fraction that does anything — total alone misleads |
| SHBG (Sex Hormone-Binding Globulin) | Explains a normal total sitting on top of a low free |
| Estradiol, Sensitive (LC/MS-MS) | The other half of the ratio, and the source of most symptoms |
| LH & FSH | Separates a testicular problem from a pituitary one |
The “Low T? Rule Out the Reversible Causes First” panel covers these in one order — 11 markers, $211.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Ketoconazole Shampoo — frequently asked questions
What is Ketoconazole Shampoo?
Ketoconazole Shampoo (Nizoral) is a hormonal & sexual research compound. Antifungal that also has weak anti-androgenic activity at the follicle and reduces Malassezia, which drives scalp inflammation.
Is the full Ketoconazole Shampoo protocol on this page?
The reported research dose is on this page, along with how Ketoconazole Shampoo works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Ketoconazole Shampoo?
Ketoconazole Shampoo has an approximate half-life of Local, which is part of what determines how often it's dosed.
What's the evidence behind Ketoconazole Shampoo?
Current evidence level: Small trials show improved hair density versus non-medicated shampoo. Ketoconazole Shampoo is offered for research purposes only and is not an approved medicine.
Ketoconazole Shampoo inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Ketoconazole Shampoo is used for
Ketoconazole Shampoo appears under 2 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Ketoconazole Shampoo is the dht & hair arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.